- Home
- CANF vs FGMCU Comparison
CANF vs FGMCU Comparison
Compare CANF & FGMCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- FGMCU
- Stock Information
- Founded
- CANF 1994
- FGMCU N/A
- Country
- CANF Israel
- FGMCU
- Employees
- CANF N/A
- FGMCU N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- FGMCU
- Sector
- CANF Health Care
- FGMCU
- Exchange
- CANF Nasdaq
- FGMCU NYSE
- Market Cap
- CANF 7.9M
- FGMCU N/A
- IPO Year
- CANF N/A
- FGMCU N/A
- Fundamental
- Price
- CANF $1.12
- FGMCU $9.85
- Analyst Decision
- CANF Strong Buy
- FGMCU
- Analyst Count
- CANF 2
- FGMCU 0
- Target Price
- CANF $14.00
- FGMCU N/A
- AVG Volume (30 Days)
- CANF 444.9K
- FGMCU N/A
- Earning Date
- CANF 05-20-2025
- FGMCU N/A
- Dividend Yield
- CANF N/A
- FGMCU N/A
- EPS Growth
- CANF N/A
- FGMCU N/A
- EPS
- CANF N/A
- FGMCU N/A
- Revenue
- CANF $674,000.00
- FGMCU N/A
- Revenue This Year
- CANF $461.72
- FGMCU N/A
- Revenue Next Year
- CANF N/A
- FGMCU N/A
- P/E Ratio
- CANF N/A
- FGMCU N/A
- Revenue Growth
- CANF N/A
- FGMCU N/A
- 52 Week Low
- CANF $1.02
- FGMCU N/A
- 52 Week High
- CANF $4.69
- FGMCU N/A
- Technical
- Relative Strength Index (RSI)
- CANF 40.25
- FGMCU N/A
- Support Level
- CANF $1.02
- FGMCU N/A
- Resistance Level
- CANF $1.20
- FGMCU N/A
- Average True Range (ATR)
- CANF 0.06
- FGMCU 0.00
- MACD
- CANF 0.01
- FGMCU 0.00
- Stochastic Oscillator
- CANF 41.30
- FGMCU 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About FGMCU FG MERGER II CORP UNIT 1 COM & 1 RT (11/02/2030)
FG Merger II Corp is a blank check company, incorporated for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (Business Combination).